DOPA COACHING’s Post

Market mood swings! Do investors overreact to USFDA actions? Let’s separate the hype from the reality. Read @HimadriBuch and @VikasReports’s insights to understand the real impact on a company’s financials. https://bit.ly/3y0JxWq

Today, we’re going to talk about Bacopa! Bacopa is fairly new to my regimen but there’s so many great reasons to consider adding it to yours. Are you using Bacopa? Let me know in the comments.

CBER Provides List of Guidances for 2024: CBER has published an updated list of guidance topics for development during 2024. #fda #financial #lifesciences

💡 Navigating NPPR registration for marketing AIFs in Germany and Denmark? Read Marc van Rijckevorsel, Alyson Yule, and Zachary Milloy’s blog first: 🔗 https://okt.to/gXjswL Here they explore the rigorous requirements for marketing AIFs in Germany and Denmark, focusing on the mandatory appointment of an EU depositary and the detailed application processes. Our team, in collaboration with Paul Hastings, is here to support your marketing inquiries and ongoing regulatory reporting needs. #AIFMD #NPPR #EURegulations #ApexGroup #FundManagement #RegulatoryCompliance

At the start of 2024, the Oracle Investment Management team made bold predictions to spark thoughtful conversations about the key issues we expected to face throughout the year. Now, revisiting those predictions, we’ve found the results to be intriguing. Read our latest blog as we look back at our predictions for 2024. #OracleInvestmentManagement #investment #predictions #results

For non-EU managers planning to raise capital in Germany and Denmark, check out the latest blog I’ve co-authored with Marc van Rijckevorsel and Alyson Yule at Apex Group Ltd (Europe) #AIFMD #privatecapital #EUregulation #NPPR

Julia's article in the latest AOPA Review highlights AOPA supporting the growth and development of the O&P and extended O&P industry workforce as identified in our current Strategic Plan. Members can read more about this on page 19 of the June 2024 Review #OandP

Market mood swings! Do investors overreact to USFDA actions? Let’s separate the hype from the reality. Read Himadri Buch and Vikas Dandekar's insights to understand the real impact on a company’s financials.

SEBI Proposes Changes to FPI Registration for ODIs and P-Notes SEBI's proposed changes to the regulatory framework for FPIs, ODIs, and P-Notes aim to boost transparency and reduce regulatory arbitrage in India's financial markets. https://shorturl.at/SJmy2 #SEBI #ODI #FPI #PNotes #RegulatoryFramework

Discover how the recent GDUFA III changes are revolutionizing the ANDA submission process in Diluks De Silva's insightful article! 📝🔍 Stay ahead of the curve with these key revisions for smoother regulatory pathways. https://lnkd.in/efUUVGyb #GDUFAIII #ANDASubmissions #FDAChanges